JAC Advance Access originally published online on April 25, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Antimicrobial Chemotherapy (2003) 51, 1323-1325
© 2003 The British Society for Antimicrobial Chemotherapy
Leading Article |
Stretching the mutant prevention concentration (MPC) beyond its limits
1 Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Manitoba; Departments of 2 Clinical Microbiology and 3 Medicine, Health Sciences Centre, Winnipeg, Manitoba, Canada
Keywords: mutant prevention concentration, resistance mechanisms
| The first 10% of the full text of this article appears below. |
Antibiotic resistance is increasingly recognized as a serious global problem. The mutant prevention concentration (MPC) is a novel concept1 that has been employed in the evaluation of an antibiotics ability to minimize or limit the development of resistant organisms.2 The MPC has been defined as the MIC of the least susceptible single-step mutant.1,2 By definition, cell growth in the presence of antibiotic concentrations greater than the MPC requires an organism to have developed two or more resistance-causing spontaneous chromosomal point mutations.1,2
The MPC concept may
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
A.-S. Kesteman, A. A. Ferran, A. Perrin-Guyomard, M. Laurentie, P. Sanders, P.-L. Toutain, and A. Bousquet-Melou Influence of Inoculum Size and Marbofloxacin Plasma Exposure on the Amplification of Resistant Subpopulations of Klebsiella pneumoniae in a Rat Lung Infection Model Antimicrob. Agents Chemother., November 1, 2009; 53(11): 4740 - 4748. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. D. Hermsen, L. B. Hovde, G. N. Konstantinides, and J. C. Rotschafer Mutant Prevention Concentrations of ABT-492, Levofloxacin, Moxifloxacin, and Gatifloxacin against Three Common Respiratory Pathogens Antimicrob. Agents Chemother., April 1, 2005; 49(4): 1633 - 1635. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. J Epstein, J. G Gums, and K. Drlica The Changing Face of Antibiotic Prescribing: The Mutant Selection Window Ann. Pharmacother., October 1, 2004; 38(10): 1675 - 1682. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Zhao Clarification of MPC and the mutant selection window concept J. Antimicrob. Chemother., October 1, 2003; 52(4): 731 - 731. [Full Text] [PDF] |
||||
![]() |
D. M. Livermore Overstretching the mutant prevention concentration J. Antimicrob. Chemother., October 1, 2003; 52(4): 732 - 732. [Full Text] [PDF] |
||||
![]() |
H. J. Smith, D. J. Hoban, and G. G. Zhanel Reply J. Antimicrob. Chemother., October 1, 2003; 52(4): 732 - 733. [Full Text] [PDF] |
||||


